NASDAQ · TNFA
TNF Pharmaceuticals, Inc.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
Loading market information…
NASDAQ · MDGS · USD
Stock price, dividends, earnings
Quote as of Apr 17, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Xylo Technologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Xylo Technologies Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Xylo Technologies Ltd. operates as a technology-focused enterprise, providing a comprehensive range of medical devices and related products to international markets, encompassing the United States, Europe, Asia, and Israel. The company's diverse operations are organized into several distinct segments, including Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and other divisions. Among its medical innovations is the Medigus Ultrasonic Surgical Endostapler, an advanced endoscopy system specifically utilized for treating gastroesophageal reflux disease. Xylo Technologies also develops specialized biological gels, engineered to safeguard patients against biological threats and to minimize the intrusion of allergens and viruses through the upper respiratory passages and ocular areas. Beyond its healthcare offerings, the company maintains a significant presence in the digital sector. This includes furnishing a digital advertising platform, managing various online retail outlets for consumer products on the Amazon marketplace, and operating an online platform for event management and ticketing services. Furthermore, Xylo Technologies is actively engaged in pioneering wireless battery charging technologies for vehicles and developing modular electronic vehicles. The organization, which was previously known as Medigus Ltd., officially adopted its current name, Xylo Technologies Ltd., in April 2024. Established in 1999, the company maintains its corporate headquarters in Tel Aviv-Yafo, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$1.32 |
| $98.00K |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$0.17+$0.17 (+100.0%)
Holdco Nuvo Group D.G Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 22.73% below the high.
$0.34-$0.06 (-14.97%)
Mallinckrodt plc’s quoted price sits in the lower half of its reported 52-week range, 97.87% below the high.
$1.71+$1.71 (+100.0%)
Aptose Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.04% below the high.
$0.03$0.00 (0.0%)
Gamida Cell Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.22% below the high.
$0.24+$0.01 (+5.66%)
Hillstream BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.06% below the high.
$0.03$0.00 (0.0%)
Pear Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.57% below the high.
$0.59+$0.05 (+10.0%)
Ra Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.67% below the high.
